Verve Therapeutics (VERV)
(Delayed Data from NSDQ)
$6.28 USD
+0.61 (10.76%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $6.28 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VERV 6.28 +0.61(10.76%)
Will VERV be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VERV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VERV
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
VERV: What are Zacks experts saying now?
Zacks Private Portfolio Services
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls
Other News for VERV
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Verve Therapeutics Expands Board with Two New Members
Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
Verve Therapeutics appoints Nia Tatsis, Jodie Morrison to board
Cathie Wood’s top and bottom performing ARKK holdings of H1